GlassScriptPhysician profile
Alvin B Coda
NPI 1588989487
$158,932.00
in general payments reported to CMS, 2019-2025
38 companies · $67K in 2025
The $67K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $2,920 · 2021: $3,891 · 2022: $22K · 2023: $12K · 2024: $31K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $19K · Food and Beverage: $13K · Travel and Lodging: $5,846 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,440 · Education: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,018.57 |
| Consulting Fee | $18,625.00 |
| Food and Beverage | $12,954.29 |
| Travel and Lodging | $5,846.38 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,440.00 |
| Education | $598.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $47,633.31 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Ucb, INC. | $34,913.47 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $31,410.80 | 2019-2025 | |
| Galderma Laboratories, L.P. | $10,711.60 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $9,143.88 | 2019-2025 | |
| Leo Pharma INC. | $5,793.83 | 2022-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $5,516.98 | 2019-2020 | |
| Incyte Corporation | $3,434.29 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $1,986.56 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,763.31 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Lilly USA, LLC | $948.29 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $933.53 | 2021-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $922.72 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $665.06 | 2019-2025 | |
| Dermavant Sciences, INC. | $616.93 | 2023-2024 | Vtama |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $584.15 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $447.44 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $259.40 | 2020-2022 | |
| Avita Medical Americas, LLC | $250.00 | 2023 | Recell |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.32 | 2023-2025 | Spevigo |
| Almirall LLC | $110.32 | 2019-2024 | Klisyri |
| Celgene Corporation | $104.23 | 2019 | |
| Verrica Pharmaceuticals INC. | $84.04 | 2024-2025 | Ycanth |
| Dermira, INC. | $67.55 | 2019-2021 | |
| Smith+Nephew, INC. | $63.09 | 2024 | Stravix |
| Vyne Pharmaceuticals INC. | $45.21 | 2020-2021 | |
| Integra Lifesciences Corporation | $43.67 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Aclaris Therapeutics, INC. | $43.12 | 2019 | |
| Convatec INC. | $38.28 | 2024-2025 | |
| Prugen, INC. Pharmaceuticals | $38.24 | 2019 | |
| Organon LLC | $36.02 | 2025 | Vtama |
| Chiesi USA, INC. | $25.84 | 2024 | Filsuvez |
| Hill Dermaceuticals, INC. | $24.99 | 2025 | Tolak |
| Kerecis Limited | $20.98 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sensus Healthcare, INC. | $19.17 | 2019 | |
| Merck Sharp & Dohme LLC | $18.17 | 2019 | |
| Mission Pharmacal Company | $14.40 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Coda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.